A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

Also called NCT07668388

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07668388
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Australia, Germany, Hungary, Poland, Romania, Slovakia, South Korea, Spain (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07668388. Randomized; quadruple masking; primary purpose treatment. Start 2026-06-22 (actual); primary completion 2027-10-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
UBT251
Intervention (Drug)
UBT251 Placebo
Intervention (Drug)
Semaglutide
Intervention (Drug)
Semaglutide Placebo
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct07668388
Content hash
1641e104f412232ee3e855417de4923efe95ededac775d3776c20f646e910009